The mechanism of action of trastuzumab (Herceptin), a monoclonal antibody that is approved for the treatment of early-stage breast cancer that is HER2-positive.
Trastuzumab (Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Herceptin is approved for the treatment of early-stage breast cancer that isHumanEpidermal growth factorReceptor2
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
May 3rd 2024During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Read More